Sanofi Dengue Bid Seen as $2.6 Billion Hit or Major Flop

An article from Bloomberg News
August 4, 2013
Sanofi Dengue Bid Seen as $2.6 Billion Hit or Major Flop

 

August 4, 2013 -- Sanofi (SAN), whose vaccines have all but eradicated polio, recently flew journalists from around the globe to a sparkling new factory in France to tout its next big project -- the world’s first vaccine for dengue.

That takes confidence, considering mid-stage studies for the shot last year yielded results that ranged from perplexing to disappointing. Sanofi is forging ahead. It’s readying commercial production of a vaccine to prevent the debilitating and sometimes fatal mosquito-borne malady that’s had outbreaks in the U.S. and Europe and threatens half the global population.

The drug maker is making the first batches of the shot at its new 300 million-euro ($398 million) plant, even as it waits for results next year of make-or-break trials to determine whether the product will be a $2.6 billion-a-year success or an $800 million flop.

Read the rest of the article here.

Common Disease Taxonomy: